Alnylam Pharmaceuticals Inc

Alnylam pioneered the therapeutic application of RNA interference (RNAi)—a biological mechanism that silences specific genes—turning a Nobel Prize-winning scientific discovery into approved drugs. Its medicines target the genetic root causes of rare diseases that were previously untreatable, including hereditary transthyretin amyloidosis (Amvuttra, Onpattro) and primary hyperoxaluria. Its Leqvio, developed with Novartis partner, applies the same platform to lower LDL cholesterol with twice-yearly injections—a potential blockbuster in a massive market.

Alnylam's investment case is a platform story: the same RNAi delivery technology that works for one gene target can theoretically be adapted to silence others, giving it a pipeline depth that single-drug biotechs lack. Multiple approved products de-risk the near-term revenue base. The Leqvio partnership with Novartis provides commercial validation and milestone payments without Alnylam bearing full launch costs. Risks include clinical failure of pipeline candidates, pricing pressure in rare diseases, and competition from other gene-silencing platforms.

Ionis Pharmaceuticals is the most direct competitor, developing antisense oligonucleotide (ASO) drugs that also silence genes—a different chemistry but overlapping disease targets. Arrowhead Pharmaceuticals uses RNAi technology similar to Alnylam's for liver-targeted diseases. Dicerna Pharmaceuticals, acquired by Novo Nordisk, expands that company into the RNAi space directly. In cholesterol lowering, Leqvio competes with PCSK9 inhibitor antibodies from Amgen (Repatha) and Sanofi/Regeneron (Praluent).

Alnylam holds foundational intellectual property in RNAi therapeutics and has built a proprietary lipid nanoparticle delivery system that safely targets liver cells—where many disease-causing proteins are produced. Having multiple approved drugs from the same platform is rare in biotech and de-risks the technology itself. The Leqvio cholesterol opportunity, if it achieves broader cardiovascular market penetration, could represent a step-change in Alnylam's commercial scale beyond the rare disease market it currently serves.

ALNY last closed at $308.05, up 0.45% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $205.87 and a high of $495.55. The current price represents 35% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 36 analysts covering ALNY, the consensus rating is Strong Buy — 28 rate it a buy, 8 hold, and 0 sell. The average price target sits at $102.31, implying 67% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Alnylam Pharmaceuticals Inc generated $3.55B in revenue during fiscal year 2026, with $300.27M reaching the bottom line as net income. The net profit margin of 8.5% reflects the competitive nature of its industry.

ALNY trades at a P/E ratio of 139.73 on trailing earnings of $2.25 per share. That's well above the S&P 500 historical average of ~20-25x, which typically signals that investors are pricing in aggressive future growth. Comparing this multiple against Biotechnology sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -23.10% (3M), -30.99% (6M), +9.64% (1Y), -23.02% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether ALNY is outperforming or lagging the broader market.